CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CURIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.38−0.03 (-6.26%)
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
CURIS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development, net | – | – | – | – | – | – | – | $7.00K | $49.00K | – | – |
| Research and Development, Net | – | – | – | – | – | – | – | $100.00K | $200.00K | – | – |
| Royalties | – | – | – | – | $10.75M | $10.72M | $10.42M | $10.42M | $9.85M | – | – |
| Contra revenue, net | – | – | – | -$116.00K | -$101.00K | -$103.00K | -$414.00K | $7.00K | – | – | – |
| Research and Development, Net | – | – | – | – | – | $100.00K | $100.00K | $100.00K | – | – | – |
| Other revenue | – | – | – | $0 | $1.00K | $214.00K | $0 | – | – | – | – |
| Royalties | – | – | – | $10.28M | $10.75M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Curis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.